Biological Age, NAD+ and ACT: ALIV's Integrated Longevity Approach | ALIV

ALIV's longevity clinical philosophy rests on a simple but important observation: biological ageing operates through multiple concurrent mechanisms, and the most comprehensive longevity interventions address more than one simultaneously. The two most clinically tractable mechanisms — mitochondrial dysfunction and regenerative cell depletion — are targeted by two distinct ALIV modalities: NAD+ IV therapy and ACT. Understanding how these two approaches complement each other explains why ALIV's most committed longevity patients combine them.

The Mitochondrial Axis: What NAD+ Addresses

Mitochondria — the cellular organelles responsible for producing ATP, the universal energy currency of cellular life — decline in number and function with age. This mitochondrial decline is partly driven by the reduction in NAD+ (nicotinamide adenine dinucleotide) — an essential cofactor in the mitochondrial electron transport chain. NAD+ also activates sirtuins — the longevity proteins that regulate DNA repair, metabolic flexibility, and stress resistance — and PARP enzymes that maintain genomic integrity. NAD+ levels decline approximately 50% between the ages of 40 and 60. IV NAD+ replenishment directly addresses this decline, restoring mitochondrial function, sirtuin activity, and cellular energy production in a way that oral NAD+ precursors (NMN, NR) approach more slowly and less completely. See: NAD+ therapy in India — the complete guide.

The Regenerative Axis: What ACT Addresses

Alongside mitochondrial decline, biological ageing involves progressive depletion of the resident tissue progenitor cell populations that maintain tissue homeostasis. These progenitor cells — present in bone marrow, adipose tissue, and multiple organ-specific niches — divide to replace damaged cells and maintain tissue architecture throughout life. With age, their number falls, their regenerative activity declines, and their paracrine signalling capacity weakens. The tissue environments that depended on their maintenance become more inflammatory, less regeneratively responsive, and more susceptible to disease. ACT addresses this depleted regenerative microenvironment by introducing a concentrated paracrine signal — growth factors and MSC-derived cytokines — that reactivates the body's own remaining progenitor cells and modulates the inflammatory environment toward repair. See: restorative anti-ageing ACT.

Why the Combination Is More Than Additive

NAD+ supports the mitochondrial function of the cells being activated by ACT's paracrine signals — the progenitor cells and repair cells responding to ACT growth factors need functional mitochondria to generate the energy their upregulated repair activity requires. ACT's growth factors support the cellular environment in which mitochondrial biogenesis — stimulated by NAD+-driven sirtuin activity — produces new, functional mitochondria in ageing tissue. The two mechanisms are not competing or redundant — they are upstream-downstream complements in the same biological process of cellular restoration. The integration is mechanistically coherent, which is why ALIV's longevity programme combines them rather than treating them as alternatives.

How is biological age measured at ALIV?

Biological age assessment at ALIV uses a composite of clinically relevant markers: inflammatory age markers (CRP, IL-6, homocysteine), metabolic markers (fasting insulin, HbA1c, lipid profile), cellular markers (telomere length where assessed, NAD+ levels), and functional markers (grip strength, VO2max estimate, cognitive assessment). No single marker captures biological age completely — the composite picture is more informative than any individual marker. Pre- and post-programme comparison of this composite provides the most objective evidence of biological age response to the longevity programme.

At what age should the combined longevity programme be started?

The greatest biological impact of longevity interventions is achieved before the cumulative damage of accelerated ageing becomes very advanced — typically in the 40s to early 60s. Starting in the 40s, when NAD+ levels are declining significantly and regenerative capacity is still meaningful, produces more robust and sustainable responses than starting in the 70s when both dimensions of decline are more established. This is not an exclusion of older patients — meaningful longevity benefit is achievable at any adult age — but it is an honest statement about optimal timing for the most comprehensive outcomes.